Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.
Offering the potential benefits of streamlined scanning and intelligent automation in magnetic resonance imaging (MRI), GE Healthcare recently launched the SIGNA Experience, which combines imaging software, artificial intelligence (AI) applications and automated workflow technologies into one platform.
GE Healthcare said the four primary components of the SIGNA Experience include enhanced image quality through the next-generation imaging software SIGNA One (available on SIGNA Prime); deep learning AI applications (including AIR Recon DL) that facilitate shorter scan times and improved signal-to-noise (SNR) ratios; flexible, lightweight AIR Coils; and automated workflow technologies, such as AIRTouch, that simplify scan set-up.
The SIGNA Experience also offers visually highlighted fields for step-by-step guidance, minimal clicks to complete the MRI exam and an intuitive workflow that accommodates a variety of experience levels, according to GE Healthcare.
“SIGNA Experience was designed in response to today’s industry pressures to help achieve operational efficiency and simplicity as clinicians face a significant volume of non-urgent backlog scans caused largely by the impact of COVID-19, radiologist shortages and staff burnout,” explained Jie Xue, the president, and CEO of Magnetic Resonance for GE Healthcare. “These technologies enable scanner operators of all skill levels to get the job done without compromising quality and output.”
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.